Aberrant PSA glycosylation - A sweet predictor of prostate cancer

Nature Reviews Urology

Volumn 10, Issue 2, 2013, Pages 99-107

  Gilgunn, Sarah ^a   Conroy, Paul J ^b   Saldova, Radka ^c   Rudd, Pauline M ^c   O'Kennedy, Richard J ^b  

^a DUBLIN CITY UNIVERSITY   (Ireland)

^b DUBLIN CITY UNIVERSITY   (Ireland)

^c NATIONAL INSTITUTE FOR BIOPROCESSING RESEARCH AND TRAINING   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCAN; PROSTATE SPECIFIC ANTIGEN;

CANCER GROWTH; COHORT ANALYSIS; DISEASE MARKER; GLYCOBIOLOGY; GLYCOSYLATION; HUMAN; ONCOLOGICAL PARAMETERS; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN ANALYSIS; QUALITY OF LIFE; REVIEW; SENSITIVITY AND SPECIFICITY;

AMINO ACID SEQUENCE; ANIMALS; EARLY DETECTION OF CANCER; GLYCOSYLATION; HUMANS; MALE; MOLECULAR SEQUENCE DATA; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84873743426     PISSN: 17594812     EISSN: 17594820     Source Type: Journal    
DOI: 10.1038/nrurol.2012.258     Document Type: Review

References (98)

1. Ferlay, J., Parkin, D. M. & Steliarova-Foucher, E. Estimates of cancer incidence and mortality in Europe in 2008. Eur. J. Cancer 46, 765-781 (2010).
2. Siegel, R., Naishadham, D. & Jemal, A. Cancer statistics, 2012. CA Cancer J. Clin. 62, 10-29 (2012).
3. Lilja, H., Ulmert, D. & Vickers, A. J. Prostate-specific antigen and prostate cancer: prediction, detection and monitoring. Nat. Rev. Cancer 8, 268-278 (2008).
4. Ward, M., Catto, J. W. & Handy, F. Prostate specific antigen: biology, biochemistry and available commercial assays. Ann. Clin. Biochem. 38, 633-651 (2001).
5. Kufe, D. W. et al. (Eds) in Holland-Frei Cancer Medicine 6th edn (B. C. Decker, Hamilton, ON, USA, 2003).
6. Kirk, D. MRC study: when to commence treatment in advanced prostate cancer. Prostate Cancer Prostatic Dis. 1, 11-15 (1997).
7. Hoffman, R. M. Clinical practice. Screening for prostate cancer. N. Engl. J. Med. 365, 2013-2019 (2011).
8. Bott, S. R. J. Prostate cancer management: 2. An update on locally advanced and metastatic disease. Postgrad. Med. J. 79, 643-645 (2003).
9. Heidenreich, A. et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur. Urol. 59, 61-71 (2011).
10. Lilja, H., Oldbring, J., Rannevik, G. & Laurell, C. B. Seminal vesicle-secreted proteins and their reactions during gelation and liquefaction of human semen. J. Clin. Invest. 80, 281-285 (1987).
11. Pinsky, P. F. et al. Prostate volume and prostate-specific antigen levels in men enrolled in a large screening trial. Urology 68, 352-356 (2006).
12. Thompson, I. M. et al. Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. JAMA 294, 66-70 (2005).
13. Gleason, D. F. & Mellinger, G. T. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J. Urol. 111, 58-64 (1974).
14. Johnstone, P. A. S., Rossi, P. J., Jani, A. B. & Master, V. "Insignificant" prostate cancer on biopsy: pathologic results from subsequent radical prostatectomy. Prostate Cancer Prostatic Dis. 10, 237-241 (2007).
15. Mikolajczyk, S. D., Song, Y., Wong, J. R., Matson, R. S. & Rittenhouse, H. G. Are multiple markers the future of prostate cancer diagnostics? Clin. Biochem. 37, 519-528 (2004).
16. Young, C. Y., Andrews, P. E., Montgomery, B. T. & Tindall, D. J. Tissue-specific and hormonal regulation of human prostate-specific glandular kallikrein. Biochemistry 31, 818-824 (1992).
17. Yousef, G. M., Luo, L. Y. & Diamandis, E. P. Identification of novel human kallikrein-like genes on chromosome 19q13.3-q13.4. Anticancer Res. 19, 2843-2852 (1999).
18. Nelson, P. S. et al. Molecular cloning and characterization of prostase, an androgen-regulated serine protease with prostate-restricted expression. Proc. Natl Acad. Sci. USA 96, 3114-3119 (1999).
19. Yousef, G. M. & Diamandis, E. P. The new human tissue kallikrein gene family: structure, function, and association to disease. Endocr. Rev. 22, 184-204 (2001).
20. Lilja, H. A kallikrein-like serine protease in prostatic fluid cleaves the predominant seminal vesicle protein. J. Clin. Invest. 76, 1899-1903 (1985).
21. Lilja, H. et al. Prostate-specific antigen in serum occurs predominantly in complex with alpha 1-antichymotrypsin. Clin. Chem. 37, 1618-1625 (1991).
22. Özen, H. & Sözen, S. PSA isoforms in prostate cancer detection. Eur. Urol. Suppl. 5, 495-499 (2006).
23. Peter, J., Unverzagt, C., Krogh, T. N., Vorm, O. & Hoesel, W. Identification of precursor forms of free prostate-specific antigen in serum of prostate cancer patients by immunosorption and mass spectrometry. Cancer Res. 61, 957-962 (2001).
24. Nurmikko, P., Pettersson, K., Piironen, T., Hugosson, J. & Lilja, H. Discrimination of prostate cancer from benign disease by plasma measurement of intact, free prostate-specific antigen lacking an internal cleavage site at Lys145-Lys146. Clin. Chem. 47, 1415-1423 (2001).
25. Lundwall, A. & Lilja, H. Molecular cloning of human prostate specific antigen cDNA. FEBS Lett. 214, 317-322 (1987).
26. Kumar, A., Mikolajczyk, S. D., Goel, A. S., Millar, L. S. & Saedi, M. S. Expression of pro form of prostate-specific antigen by mammalian cells and its conversion to mature, active form by human kallikrein 2. Cancer Res. 57, 3111-3114 (1997).
27. Armbruster, D. A. Prostate-specific antigen: biochemistry, analytical methods, and clinical application. Clin. Chem. 39, 181-195 (1993).
28. Balk, S. P., Ko, Y.-J. & Bubley, G. J. Biology of prostate-specific antigen. J. Clin. Oncol. 21, 383-391 (2003).
29. Takayama, T. K., Fujikawa, K. & Davie, E. W. Characterization of the precursor of prostate-specific antigen. Activation by trypsin and by human glandular kallikrein. J. Biol. Chem. 272, 21582-21588 (1997).
30. Mikolajczyk, S. D. et al. A precursor form of PSA (pPSA) is a component of the free PSA in prostate cancer serum. Urology 50, 710-714 (1997).
31. Vickers, A. J. & Brewster, S. F. PSA velocity and doubling time in diagnosis and prognosis of prostate cancer. Br. J. Med. Surg. Urol. 5, 162-168 (2012).
32. Christensson, A. et al. Serum prostate specific antigen complexed to alpha 1-antichymotrypsin as an indicator of prostate cancer. J. Urol. 150, 100-105 (1993).
33. Catalona, W. J. et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA 279, 1542-1547 (1998).
34. Mikolajczyk, S. D., Marks, L. S., Partin, A. W. & Rittenhouse, H. G. Free prostate-specific antigen in serum is becoming more complex. Urology 59, 797-802 (2002).
35. Mikolajczyk, S. D. et al. A truncated precursor form of prostate-specific antigen is a more specific serum marker of prostate cancer. Cancer Res. 61, 6958-6963 (2001).
36. Catalona, W. J. et al. Serum pro-prostate specific antigen preferentially detects aggressive prostate cancers in men with 2 to 4 ng/ml prostate specific antigen. J. Urol. 171, 2239-2244 (2004).
37. Sokoll, L. J. et al. A Prospective, Multicenter, National Cancer Institute Early Detection Research Network study of [-2]proPSA: Improving prostate cancer detection and correlating with cancer aggressiveness. Cancer Epidemiol. Biomarkers 19, 1193-1200 (2010).
38. Mikolajczyk, S. D. & Rittenhouse, H. G. Pro PSA: a more cancer specific-form of prostate specific antigen for the early detection of prostate cancer. Keio J. Med. 52, 86-91 (2003).
39. Catalona, W. J. et al. A multi-center study of [-2]pro-prostate specific antigen (PSA) in combination with PSA and free PSA for prostate cancer detection in the 2.0 to 10.0 ng/ml PSA range. J. Urol. 185, 1650-1655 (2011).
40. Zhang, W. & Leinonen, J. Purification and characterization antigen in human seminal fluid of different molecular forms of prostate-specific antigen in human seminal fluid. Clin. Chem. 41, 1567-1573 (1995).
41. Mikolajczyk, S. D. et al. "BPSA" a specific molecular form of free prostate-specific antigen, is found predominantly in the transition zone of patients with nodular benign prostatic hyperplasia. Urology 55, 41-45 (2000).
42. Linton, H. J. et al. Benign prostate-specific antigen (BPSA) in serum is increased in benign prostate disease. Clin. Chem. 49, 253-259 (2003).
43. Okihara, K. et al. Comparative analysis of complexed prostate specific antigen, free prostate specific antigen and their ratio in detecting prostate cancer. J. Urol. 167, 2017-2024 (2002).
44. Jung, K. et al. Molecular forms of prostate-specific antigen in malignant and benign prostatic tissue: biochemical and diagnostic implications. Clin. Chem. 46, 47-54 (2000).
45. Partin, A. W. et al. Complexed prostate specific antigen improves specificity for prostate cancer detection: results of a prospective multicenter clinical trial. J. Urol. 170, 1787-1791 (2003).
46. Varki, A. et al. Essentials of Glycobiology (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, 2009).
47. Meany, D. L. & Chan, D. W. Aberrant glycosylation associated with enzymes as cancer biomarkers. Clin. Proteomics 8, 7 (2011).
48. Freeze, H. H. Genetic defects in the human glycome. Nat. Rev. Genet. 7, 537-551 (2006).
49. Arnold, J. N., Saldova, R., Hamid, U. M. A. & Rudd, P. M. Evaluation of the serum N-linked glycome for the diagnosis of cancer and chronic inflammation. Proteomics 8, 3284-3293 (2008).
50. Tharmalingam, T., Mariño, K. & Rudd, P. M. Platform technology to identify potential disease markers and establish heritability and environmental determinants of the human serum N-glycome. Carbohydr. Res. 345, 1280-1282 (2010).
51. Lauc, G., Rudan, I., Campbell, H. & Rudd, P. M. Complex genetic regulation of protein glycosylation. Mol. Biosyst. 6, 329-335 (2010).
52. Kattla, J. et al. Protein glycosylation. Compr. Biotech. 3, 467-486 (2011).
53. Mariño, K., Bones, J., Kattla, J. J. & Rudd, P. M. A systemic approach to glycosylation analysis: a path through the maze. Nat. Chem. Biol. 6, 713-723 (2010).
54. Marek, K. W., Vijay, I. K. & Marth, J. D. A recessive deletion in the GlcNAc-1-phosphotransferase gene results in peri-implantation embryonic lethality. Glycobiology 9, 1263-1271 (1999).
55. Wu, A. M., Lisowska, E., Duk, M. & Yang, Z. Lectins as tools in glycoconjugate research. Glycoconj. J. 26, 899-913 (2009).
56. Thompson, R., Creavin, A., O'Connell, M., O'Connor, B. & Clarke, P. Optimization of the enzyme-linked lectin assay for enhanced glycoprotein and glycoconjugate analysis. Anal. Biochem. 413, 114-122 (2011).
57. Royle, L., Radcliffe, C. M., Dwek, R. A. & Rudd, P. M. Detailed structural analysis of N-glycans released from glycoproteins in SDS-PAGE gel bands using HPLC combined with exoglycosidase array digestions. Methods Mol. Biol. 347, 125-143 (2006).
58. National Institute for Bioprocessing Research and Training. Glycobase 3.1. http://glycobase.nibrt.ie/glycobase/show-nibrt.action (2012).
59. Royle, L. et al. HPLC-based analysis of serum N-glycans on a 96-well plate platform with dedicated database software. Anal. Biochem. 376, 1-12 (2008).
60. Campbell, M. P., Royle, L., Radcliffe, C. M., Dwek, R. A. & Rudd, P. M. GlycoBase and autoGU: tools for HPLC-based glycan analysis. Bioinformatics 24, 1214-1216 (2008).
61. Lauc, G. et al. Genomics meets glycomics-the first GWAS study of human N-Glycome identifies HNF1α as a master regulator of plasma protein fucosylation. PLoS Genet. 6, e1001256 (2010).
62. Vitart, V. et al. SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout. Nat. Genet. 40, 437-442 (2008).
63. Bones, J., Mittermayr, S., Donoghue, N. O. & Rudd, P. M. Ultra performance liquid chromatographic profiling of serum N-glycans for fast and efficient glycosylation. Anal. Chem. 82, 10208-10215 (2010).
64. Tabarés, G. et al. Different glycan structures in prostate-specific antigen from prostate cancer sera in relation to seminal plasma PSA. Glycobiology 16, 132-145 (2006).
65. Chandrasekaran, E. V., Chawda, R., Locke, R. D., Piskorz, C. F. & Matta, K. L. Biosynthesis of the carbohydrate antigenic determinants, Globo H, blood group H, and Lewis b: a role for prostate cancer cell alpha 1, 2-L-fucosyltransferase. Glycobiology 12, 153-162 (2002).
66. Matsumoto, K. et al. N-glycan fucosylation of epidermal growth factor receptor modulates receptor activity and sensitivity to epidermal growth factor receptor tyrosine kinase inhibitor. Cancer Sci. 99, 1611-1617 (2008).
67. Liu, Y., Yen, H. & Chen, C. Sialylation and fucosylation of epidermal growth factor receptor suppress its dimerization and activation in lung cancer cells. Proc. Natl Acad. Sci. USA 108, 11332-11337 (2011).
68. Kyselova, Z. et al. Alterations in the serum glycome due to metastatic prostate cancer research articles. J. Proteome Res. 6, 1822-1832 (2007).
69. Saldova, R., Fan, Y., Fitzpatrick, J. M., Watson, R. W. G. & Rudd, P. M. Core fucosylation and alpha 2-3 sialylation in serum N.-glycome is significantly increased in prostate cancer comparing to benign prostate hyperplasia. Glycobiology 21, 195-205 (2011).
70. Peracaula, R. et al. Altered glycosylation pattern allows the distinction between prostate-specific antigen (PSA) from normal and tumor origins. Glycobiology 13, 457-470 (2003).
71. Ohyama, C. et al. Carbohydrate structure and differential binding of prostate specific antigen to Maackia amurensis lectin between prostate cancer and benign prostate hypertrophy. Glycobiology 14, 671-679 (2004).
72. Tajiri, M., Ohyama, C. & Wada, Y. Oligosaccharide profiles of the prostate specific antigen in free and complexed forms from the prostate cancer patient serum and in seminal plasma: a glycopeptide approach. Glycobiology 18, 2-8 (2008).
73. Sarrats, A. et al. Differential percentage of serum prostate-specific antigen subforms suggests a new way to improve prostate cancer diagnosis. Prostate 70, 1-9 (2010).
74. Sarrats, A. et al. Glycan characterization of PSA 2-DE subforms from serum and seminal plasma. OMICS 14, 465-474 (2010).
75. Meany, D. L., Zhang, Z., Sokoll, L. J., Zhang, H. & Chan, D. W. Glycoproteomics for prostate cancer detection: changes in serum PSA glycosylation patterns. J. Proteome Res. 8, 613-619 (2009).
76. Dwek, M. V., Jenks, A. & Leathem, A. J. C. A sensitive assay to measure biomarker glycosylation demonstrates increased fucosylation of prostate specific antigen (PSA) in patients with prostate cancer compared with benign prostatic hyperplasia. Clin. Chim. Acta 411, 1935-1939 (2010).
77. Meany, D. L., Hackler, L., Zhang, H. & Chan, D. W. Tyramide signal amplification for antibody-overlay lectin microarray: a strategy to improve the sensitivity of targeted glycan profiling. J. Proteome Res. 10, 1425-1431 (2011).
78. Vickers, A. J., Roobol, M. J. & Lilja, H. Screening for prostate cancer: early detection or overdetection? Ann. Rev. Med. 63, 161-170 (2012).
79. Botchorishvili, G., Matikainen, P. M. & Lilja, H. Early prostate-specific antigen changes and the diagnosis of prostate cancer. Curr. Opin. Urol. 19, 221-226 (2010).
80. Fan, Y. et al. Applying random forests to identify biomarker panels in serum 2D-DIGE data for the detection and staging of prostate cancer. J. Proteome Res. 10, 1361-1373 (2011).
81. Drake, P. M. et al. Sweetening the pot; adding glycosylation to the biomarker discovery equation. Clin. Chem. 56, 223-236 (2010).
82. Sato, Y. et al. Early recognition of hepatocellular carcinoma based on altered profiles of alpha-fetoprotein. N. Engl. J. Med. 328, 1082-1086 (1993).
83. Moriwaki, K. et al. A high expression of GDP-fucose transporter in hepatocellular carcinoma is a key factor for increases in fucosylation. Glycobiology 17, 1311-1320 (2007).
84. Bradbury, A. R. M., Sidhu, S., Dübel, S. & McCafferty, J. Beyond natural antibodies: the power of in vitro display technologies. Nat. Biotech. 29, 245-254 (2011).
85. Conroy, P. J., Hearty, S., Leonard, P. & O'Kennedy, R. J. Antibody production, design and use for biosensor-based applications. Semin. Cell Dev. Biol. 20, 10-26 (2009).
86. Ayyar, B. V., Hearty, S. & O'Kennedy, R. Highly sensitive recombinant antibodies capable of reliably differentiating heart-type fatty acid binding protein from noncardiac isoforms. Anal. Biochem. 407, 165-171 (2010).
87. Conroy, P. J., O'Kennedy, R. J. & Hearty, S. Cardiac troponin I: a case study in rational antibody design for human diagnostics. Protein Eng. Des. Sel. 25, 295-305 (2012).
88. Hayes, C. J., Leonard, P. & O'Kennedy, R. Overcoming antibody expression and screening limitations by smart design: Applications to PSA immunoassay development. Protein Expr. Purif. 83, 84-91 (2012).
89. Healy, D., Hayes, C. J., Leonard, P., McKenna, L. & O'Kennedy, R. Biosensor developments: application to prostate-specific antigen detection. Trends Biotechnol. 25, 125-131 (2007).
90. Thaxton, C. S. et al. Nanoparticle-based bio-barcode assay redefines "undetectable" PSA and biochemical recurrence after radical prostatectomy. Proc. Natl Acad. Sci. USA 106, 18437-18442 (2009).
91. Hearty, S., Leonard, P. & O'Kennedy, R. Nanomedicine: barcodes check out prostate cancer. Nat. Nanotech. 5, 9-10 (2010).
92. Stura, E. A. et al. Crystal structure of human prostate-specific antigen in a sandwich antibody complex. J. Mol. Biol. 414, 530-544 (2011).
93. Muller, B. H. et al. In vitro affinity maturation of an anti-PSA antibody for prostate cancer diagnostic assay. J. Mol. Biol. 414, 545-562 (2011).
94. Hoeks, C. M. A. et al. Prostate cancer: multiparametric MR imaging for detection, localisation, and staging. Radiology 261, 46-62 (2011).
95. Oon, S. F., Pennington, S. R., Fitzpatrick, J. M. & Watson, R. W. G. Biomarker research in prostate cancer-towards utility, not futility. Nat. Rev. Urol. 8, 131-138 (2011).
96. Hassan, O., Ahmad, A., Sethi, S. & Sarkar, F. H. Recent updates on the role of microRNAs in prostate cancer. J. Hem. Oncol. 5, 9 (2012).
97. Jerónimo, C. et al. Epigenetics in prostate cancer: biologic and clinical relevance. Eur. Urol. 60, 753-766 (2011).
98. Harvey, D. J. et al. Proposal for a standard system for drawing structural diagrams of N- and O-linked carbohydrates and related compounds. Proteomics 9, 3796-3801 (2009).